Frequently Asked Questions
Answers to common questions about visits, conditions and treatment.
- Medically reviewed by Dr. Alexis David, MD
- Updated
- Sources
- Editorial policy
General
Referral rules depend on your insurance plan. Contact the office to ask about scheduling a first visit.
Payment policies are set by Premier Medical Weight Management. Its website currently says the practice is out of network with insurance plans and is not an option for Medicare patients, and that it provides paperwork some patients use to seek reimbursement. Confirm current details with the office. Confirm insurance and payment wording with the practice
A detailed conversation about your weight history, health and goals, a physical exam, a review of recent labs and a body composition assessment. You leave with a starting plan.
No. Dr. David's practice provides medical, nonsurgical care. If surgery may be a good fit for you, a referral to a surgical program can be discussed.
Yes. Obesity is a chronic disease, not a personal failure. Visits are private and respectful, and care uses person-first language.
Medications
Approved options for chronic weight management include semaglutide (Wegovy, as a weekly injection or a daily pill), tirzepatide (Zepbound), orforglipron (Foundayo, a daily pill), liraglutide 3.0 mg (Saxenda), phentermine-topiramate ER (Qsymia), naltrexone-bupropion ER (Contrave), and orlistat. Phentermine alone is approved for short-term use. 312 New options keep arriving, so ask what is currently available.
In general, adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition, may be candidates. Your full health history, other medicines and preferences guide the choice.
Nausea, diarrhea, constipation and vomiting are the most common. They are usually mild to moderate and happen most often when the dose goes up. 4
Weight often returns. In the STEP 4 trial, people switched from semaglutide to placebo regained weight over the following year. 5 Any change should be planned with your doctor.
Compounded products are not FDA-approved, and their quality can vary. Talk with your doctor before using any product that isn't an FDA-approved medicine from a licensed pharmacy.
No. Medicines may be suggested, but they are never required. Many people work on nutrition, activity and behavior support alone.
Nutrition & Lifestyle
Not necessarily. Care focuses on the kinds of foods you eat and building a sustainable pattern, not a strict calorie number.
Mostly whole foods, with an emphasis on protein, vegetables and fiber. Guidance is adjusted for your preferences, culture and household.
Exercise is not required to start. Moving more during the day and adding strength activity over time help protect muscle and support health.
Eat enough protein, spread through the day, and do strength activity at least twice a week. Body composition checks help track lean mass over time. 6
Please mention it at your visit. Screening for disordered eating is part of the evaluation, and care is adjusted to put your safety and wellbeing first. A referral to an eating disorder specialist may be the best first step.
Sources and references
- Novo Nordisk. Wegovy pill approved in the US as the first oral GLP-1 for weight management. December 2025. View source
- Healio. FDA approves orforglipron, an oral GLP-1, for adults with obesity. April 1, 2026. View source
- Grunvald E, Shah R, Hernaez R, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022;163(5):1198-1225. View source
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. View source
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. View source
- Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl 4):16-27. View source
Ready to talk about your weight and health?
Start with a private, judgment-free conversation about your goals and options.